Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
Lee's Pharm (00950.HK) has appointed Huang Ruijin as a non-executive director.
Lee's Pharm (00950.HK) announced on July 2nd that, considering the proposal of the company's nomination committee, the board of directors has appointed Huang Ruijia as a non-executive director, effective from July 2nd, 2024.
Lee's pharm granted a total of 1.764 million share purchase rights.
Lee's Pharm (00950) announced that on June 20, 2024, it granted a total of 1,764,000 share options under the share option plan. The exercise price of the share option is HK$1.2 per share.
Lee's Pharm (00950) has granted a total of 1.764 million share purchase rights.
Lee's Pharm (00950) announced that on June 20, 2024, it granted options under the stock option plan for subscription...
Lee's Pharm (00950.HK) has received a shareholding of 100,000 shares from director Li Ye Ni.
On June 19, 2024, Lee's Pharm (00950.HK) was reported to have received an increase in shareholdings of 100,000 shares by executive director Li Yeni at an average price of HKD 1.20 per share, involving approximately HKD 12,000. After the shareholding, Li Yeni's latest shareholding number rose from 21.62% to 21.63%, holding a total of 127,379,625 shares.
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
Lee's Pharmaceutical Company (00950.HK) was increased by 147,500 shares by Executive Director Li Yeni
Gelonghui, May 9 | According to the Stock Exchange's latest equity disclosure data, from May 2 to May 3, 2024, Lee's Pharmaceuticals (00950.HK) was granted an increase of 147,500 shares at an average price of HK$1.1447-1.18 per share on the market, involving approximately HK$170,000. After increasing her holdings, Li Ye-ni's latest shareholding was 127,099,625 shares, and the shareholding ratio increased from 21.56% to 21.58%.
Lee's Pharmaceutical's 2023 Profit Slumps 67%
Lee's Pharmaceutical Holdings (HKG:0950) recorded a 67% decline in attributable profit for the year ended Dec. 31, 2023, to HK$16.7 million from HK$51.3 million in 2022, a Friday filing on the Hong Ko
LEE'S PHARM: Annual Report 2023
LEE'S PHARM To Go Ex-Dividend On May 28th, 2024 With 0.01 HKD Dividend Per Share
March 27th - $LEE'S PHARM(00950.HK)$ is trading ex-dividend on May 28th, 2024. Shareholders of record on May 29th, 2024 will receive 0.01 HKD dividend per share on June 17th, 2024. The ex-dividend
Lee's Pharmaceuticals (00950) will pay a final dividend of HK$0.01 per share on June 17
Lee's Pharmaceutical (00950) announced that it will be distributed on June 17, 2024 until December 2023...
Lee's Pharmaceuticals (00950.HK): Net profit of HK$16.698 million decreased by 67.4% year-on-year in 2023
Gelonghui, March 26, 丨 Lee's Pharmaceutical (00950.HK) announced that for the year ended December 31, 2023, revenue was approximately HK$1,053 million, down 14.6% year on year; profit attributable to company owners was approximately HK$166.98 million, a decrease of 67.4% year on year; basic profit per share was HK2.84 cents, with a proposed final dividend of 1 HK cent per share. During the reporting period, the Group recorded gross profit of HK$551 million, a decrease of 28.5% over the previous year, in line with the decline in sales. The Group's gross margin for the year was 52.4%, down 10.1 from 62.5% in 2022
LEE'S PHARM: Announcement of Annual Results for the Year Ended 31 December 2023
Lee's Pharmaceutical Company (00950.HK) plans to hold a board meeting on March 26 to approve the annual results
Glonghui, March 14, 丨 Lee's Pharmaceutical (00950.HK) announced that the company's board of directors meeting will be held on March 26, 2024 (Tuesday) on the 1st floor of Building 20E, Science Park Phase III Science Park East, Shatin, New Territories, Hong Kong to review (including) and approve (if deemed appropriate) the publication of the company's and its subsidiaries' annual results announcements for the year ended 31 December 2023 and consider the proposed final dividend (if any).
LEE'S PHARM: Notice of Board Meeting
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Pioneer Securities Pharmaceutical's 24-year Strategy: Risks have been fully released, and subsequent industry valuations are expected to rise steadily
The Zhitong Finance App learned that Pioneer Securities released a research report saying that due to more scientific collection rules, after the collection gradually covered a large stock of generic drugs/high-value consumables, the performance was clear, and new performance growth points were formed after innovative products were launched one after another, and the drugs/device-related companies in the hospital will usher in a new growth cycle after their performance stabilizes.
No Data